Drug Profile
67Cu MeCOSar Octreotate - Clarity Pharmaceuticals
Alternative Names: 67-Cu-SARTATE; copper-67 labelled MeCOSar-Tyr3-octreotate; SARTATE™ NETs Therapy - Clarity Pharmaceuticals; SARTATE™ Therapy - Clarity PharmaceuticalsLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Clarity Pharmaceuticals
- Class Antibodies; Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuroendocrine tumours
- Phase I/II Meningioma; Neuroblastoma
Most Recent Events
- 17 Jul 2020 Phase-I/II clinical trials in Neuroblastoma (In adults, In children, In the elderly) in USA (IV) (NCT04023331)
- 03 Jun 2020 67Cu MeCOSar Octreotate receives Rare Pediatric Disease Designation for Neuroblastoma in USA
- 28 May 2020 No recent reports of development identified for preclinical development in Neuroblastoma in Australia (Parenteral)